Arcturus Therapeutics Holdings Inc.
ARCT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.88 | 0.28 | 0.10 | 0.00 |
| FCF Yield | -3.40% | -1.63% | -12.24% | -0.06% |
| EV / EBITDA | -25.47 | -16.56 | -7.04 | -13.99 |
| Quality | ||||
| ROIC | 1.58% | -4.36% | -5.81% | -11.69% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 1.28 | 0.63 | 2.50 | 0.01 |
| Growth | ||||
| Revenue 3-Year CAGR | -32.13% | -24.52% | -21.65% | -12.42% |
| Free Cash Flow Growth | -195.63% | 83.62% | -12,272.54% | 98.79% |
| Safety | ||||
| Net Debt / EBITDA | 11.79 | 16.01 | 10.88 | 11.68 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 41.72 | 63.17 | 44.64 | 17.03 |